PHILADELPHIA — The American Association for Cancer Research announces a call for nominations for the Seventh Annual AACR Team Science Award.
The AACR Team Science Award recognizes an outstanding interdisciplinary research team for its innovative and meritorious scientific work that has advanced or will likely advance our fundamental knowledge of cancer, or a team that has applied existing knowledge to advance the detection, diagnosis, prevention or treatment of cancer.
The award will be presented during the opening ceremony of the AACR Annual Meeting 2013, which will be held April 6-10, 2013, in Washington, D.C.
Last year’s award was presented to The Institute of Cancer Research (ICR) and The Royal Marsden Hospital: Cancer Research U.K. Cancer Therapeutics Unit and Drug Development Unit, led by Paul Workman, Ph.D., D.Sc., F.Med.Sci., Harrap professor of pharmacology and therapeutics and deputy chief executive at the ICR, as well as head of the division of cancer therapeutics and director of the Cancer Research U.K. Cancer Therapeutics Unit. The team’s many research accomplishments include the development of abiraterone, which is used to treat castration-resistant prostate cancer by inhibiting the enzyme CYP17A1, an enzyme required for the body’s production of testosterone.
The Seventh Annual AACR Team Science Award is generously supported by a $50,000 honorarium from Eli Lilly and Company.